>
产品中心 >
monoclonal_antibody >
BioXcell/InVivoMAb抗小鼠IL-1 R（CD121a）/大于100 MG的量：（仅报价）/BE0256-CUST
About InVivoMAb anti-mouse CD69
The CD69.2.2 monoclonal antibody reacts with mouse CD69, an 85 kDa type II C-type lectin. CD69 expression is rapidly induced upon cell activation in all leukocytes. CD69 is thought to be a negative regulator of the immune response in part through modulating the production of TGF-β. Studies in CD69-deficient mice have revealed that CD69 plays crucial roles in the pathogenesis of various inflammatory diseases including arthritis, asthma, and colitis. When administered in vivo the CD69.2.2 antibody causes CD69 to be internalized but does not deplete CD69+ cells. Anti-CD69-treated mice resemble CD69-/- mice to a remarkable degree. The CD69.2.2 antibody has been shown to activate NK cells in vivo and in vitro and promote anti-tumor responses.
InVivoMAb anti-mouse CD69 Specifications
| Isotype | Mouse IgG1, κ |
| Recommended Isotype Control(s) | InVivoMAb mouse IgG1 isotype control, unknown specificity(BE0083) |
| Recommended InVivoPure Dilution Buffer | InVivoPure pH 7.0 Dilution Buffer(IP0070) |
| Immunogen | CD69+ murine 300-19 pre-B cells |
| Reported Applications |
|
| Formulation |
|
| Endotoxin |
|
| Purity |
|
| Sterility | 0.2 μM filtered |
| Production | Purified from tissue culture supernatant in an animal free facility |
| Purification | Protein A |
| Molecular Weight | 150 kDa |
| Storage | The antibody solution should be stored at the stock concentration at 4°C. Do not freeze. |
